Fujifilm Diosynth Biotechnologies

Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina

Retrieved on: 
Thursday, April 11, 2024
Nitrogen oxide, Fujifilm Diosynth Biotechnologies, Solar energy, Monoclonal antibody, Town, Water, Carbon, Growth, CDMO, Environment, Life, Certification, LEED, Bioreactor, Patient, Gold, Fujifilm, Spacecraft, Renewable energy

TOKYO, April 11, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Corporation today announced an investment of $1.2 billion in its Large-Scale Cell Culture CDMO* Business to further expand the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion.

Key Points: 
  • TOKYO, April 11, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Corporation today announced an investment of $1.2 billion in its Large-Scale Cell Culture CDMO* Business to further expand the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion.
  • The expansion adds significant large-scale production capacity to FUJIFILM Diosynth Biotechnologies’ global network through its United States and Europe manufacturing hubs.
  • The investment will generate an additional 680 jobs by 2031, also bringing the total number of new, highly skilled local jobs to 1400 in Holly Springs.
  • Over the course of the 12-year term of this grant, the project is estimated to grow the state’s economy by $4.7 billion.

Azzur Group Names Project Management Expert, Rob Chapman, Director of its Raleigh-Based Consulting Operation

Retrieved on: 
Wednesday, April 17, 2024
Fujifilm Diosynth Biotechnologies, Corps, Engineer, PMP, ATMP, Azur, Management, GxP, Southeastern United States, Quality, Risk management, Engineering, Therapy, Science, Patient, Society, GMP, United States service academies, Construction

RALEIGH, N.C., April 17, 2024 /PRNewswire/ -- Azzur Group today announces the appointment of Rob Chapman to Director of Azzur Raleigh, Azzur Group's GxP advisory and consulting operation serving the burgeoning life science industry in the Southeastern U.S.

Key Points: 
  • RALEIGH, N.C., April 17, 2024 /PRNewswire/ -- Azzur Group today announces the appointment of Rob Chapman to Director of Azzur Raleigh, Azzur Group's GxP advisory and consulting operation serving the burgeoning life science industry in the Southeastern U.S.
  • Rob brings to Azzur Group more than 30 years of engineering and project management experience in the regulated pharmaceutical and life science space, with expertise in lean project management, process improvement, change and risk management, and project visualization.
  • "I am excited to embark on the next step of my career with Azzur Group," said Rob.
  • "We're grateful for the opportunity to welcome Rob to the Azzur Consulting team," said Allison Kerska , President, Azzur Consulting and Azzur Training Center.

FUJIFILM Diosynth Invests $1.2B in Holly Springs, North Carolina, Manufacturing Facility, Creating 680 New Jobs

Retrieved on: 
Thursday, April 11, 2024
Dai, University, Fujifilm Diosynth Biotechnologies, Raleigh, North Carolina, Environmental quality, Investment, Toyota, Transport, Duke Energy, State university system, Dominion Energy, Partnership, Town, CDMO, Honda HA-420 HondaJet, Drug, Sumitomo Forestry, Commerce, North Carolina State University, Wake Technical Community College, Economic development, Biotechnology, Fine chemical

HOLLY SPRINGS, N.C., April 11, 2024 /PRNewswire-PRWeb/ -- FUJIFILM Diosynth Biotechnologies North Carolina, Inc., a world-leading contract development and manufacturing organization (CDMO), will invest $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, North Carolina, creating 680 new jobs in Wake County. Initial investments of the FUJIFILM's Holly Springs operation included $2 billion in 2021, making it the largest end-to-end biopharmaceutical manufacturing facility in North America.

Key Points: 
  • Initial investments from FUJIFILM Diosynth included $2 billion in 2021, making it the largest end-to-end biopharmaceutical manufacturing facility in North America
    HOLLY SPRINGS, N.C., April 11, 2024 /PRNewswire-PRWeb/ -- FUJIFILM Diosynth Biotechnologies North Carolina, Inc., a world-leading contract development and manufacturing organization (CDMO), will invest $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, North Carolina, creating 680 new jobs in Wake County.
  • "North Carolina is known worldwide as a biotechnology hub thanks to the continued investment from companies like FUJIFILM Diosynth," said Christopher Chung, CEO of the Economic Development Partnership of North Carolina.
  • "North Carolina is known worldwide as a biotechnology hub thanks to the continued investment from companies like FUJIFILM Diosynth," said Christopher Chung, CEO of the Economic Development Partnership of North Carolina.
  • In 2021, Toyota announced it would build its first North American battery manufacturing plant in Liberty, North Carolina, investing $1.29 billion and creating 1,750 jobs.

FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer

Retrieved on: 
Monday, March 11, 2024
CFO, Head, Potyvirus, Life, Growth, Novo Nordisk, Alston & Bird, Vaccine, CDMO, History, Financial management, Small Business Saturday, Partner, Fujifilm Diosynth Biotechnologies, Management

In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.

Key Points: 
  • In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.
  • We look forward to Richard’s contributions as we execute on our growth strategy," said Lars Petersen, president and chief executive officer of FUJIFILM Diosynth Biotechnologies.
  • Prior to joining FUJIFILM Diosynth Biotechnologies, he held leadership roles at Novo Nordisk and Alston & Bird LLP.
  • To find more information on all members of the FUJIFILM Diosynth Biotechnologies Executive Leadership team please visit: www.fujifilmdiosynth.com/leadership

Fujifilm Celebrates Recent Recipients of Fujifilm Fellowships at Harvard Medical School

Retrieved on: 
Tuesday, February 20, 2024
Lilium, Therapy, Research, Doctor of Philosophy, Drug resistance, Chemical biology, G protein-coupled receptor, Biology, Obesity, Pain, MIT, Harvard University, Drug discovery, Eurosport 1, Health, Fujifilm, Faculty (division), Disease, Massachusetts General Hospital, Harvard Medical School, Infection, Publication, Faculty, Fujifilm Diosynth Biotechnologies, Management

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.
  • These PhD students from around the world are part of the Harvard Medical School Therapeutics Graduate Program working to advance therapeutics discovery, development, and applications to improve the treatment of disease.
  • Launched with six fellows in 2019, the Fujifilm Fellowship has now grown to reach 34 recipients to date, including six alumni.
  • “Fujifilm is proud to support Harvard Medical School as it helps to shape our world’s future scientists.

VGXI Welcomes Michael Stewart as New Chief Operating Officer

Retrieved on: 
Monday, March 4, 2024
Engineering, DOD, Chemistry, Growth, Hospital, Retirement, GMP, Child, University, CDMO, Doctor of Philosophy, RNA, Organization, Fujifilm Diosynth Biotechnologies, University system, Consciousness, Research, DNA, St. Jude's, Biochemistry

CONROE, Texas, March 4, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, proudly announces the appointment of Michael Stewart as its new Chief Operating Officer (COO).

Key Points: 
  • CONROE, Texas, March 4, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, proudly announces the appointment of Michael Stewart as its new Chief Operating Officer (COO).
  • Stewart brings over 20 years of extensive experience in the viral vector therapy and vaccine production industry, which will be instrumental to VGXI's continued growth and success.
  • "We are thrilled to welcome Michael Stewart to VGXI as our new Chief Operating Officer," said VGXI's CEO, Young Park.
  • Please join VGXI in extending a warm welcome to Michael Stewart as he assumes his new role as Chief Operating Officer, effective immediately.

Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities

Retrieved on: 
Monday, December 4, 2023
Biology, CTL, Fujifilm Diosynth Biotechnologies, Drug discovery, Cell, Research, TCR, Health, CDMO, IPSC, Tissue, CGMP, Drive, Laboratory, USD, Nature, Fujifilm, Pharmacology, NK

TOKYO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces the investment of USD 200 million in two subsidiaries to significantly expand global cell therapy contract development and manufacturing (CDMO) capabilities.

Key Points: 
  • TOKYO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces the investment of USD 200 million in two subsidiaries to significantly expand global cell therapy contract development and manufacturing (CDMO) capabilities.
  • The investment will enable Fujifilm to support the expanding cell therapy market which is anticipated to grow by more than 30% per year up from USD 3.3 billion in FY2022 [1] .
  • This investment will double the Company’s existing manufacturing capacity for the development and commercialization of iPSC-derived cell therapies for its partners.
  • “This investment is an important step for Fujifilm to lead as an innovative global manufacturing partner for the growing cell therapy market.

Cell Line Development Market Research Report 2023-2030 Featuring Key Players - Thermo Fisher Scientific, Corning, Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius, Merck, Berkeley Lights, Danaher - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Health, Pharmaceutical, CLD, Research, Immortalised cell line, GMP, Thermo Fisher Scientific, Fujifilm, Type, Coronavirus, Application, Fujifilm Diosynth Biotechnologies, ATCC (company), Novartis, Sigma-Aldrich, Human, Growth, ATCC, Fine chemical, Pharmaceutical industry, Mobile phone, Vaccine, Nusinersen

Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.

Key Points: 
  • Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.
  • The expansion and growth of the biologics sector will also be a major CLD market development determinant.
  • For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021.
  • However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.

Global Biologics CDMO Market Skyrockets to Nearly $13.4 Billion in 2022, Set to Reach $27 Billion by 2028 Driven by Rising R&D Activities and Demand for Biologics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Other Manufacturing, Manufacturing, Fujifilm Diosynth Biotechnologies, Research, Ageing, Biotechnology, Prevalence, Conditional sentence, CDMO, FDB, R, Drug development, American Biological Safety Association, Growth, Research and development, Compound annual growth rate, Pharmaceutical industry, Generic drug, Fine chemical

The global Biologics Contract Development and Manufacturing Organization (CDMO) market witnessed remarkable growth, reaching a value of nearly $13.4 billion in 2022.

Key Points: 
  • The global Biologics Contract Development and Manufacturing Organization (CDMO) market witnessed remarkable growth, reaching a value of nearly $13.4 billion in 2022.
  • Similarly, the Asia-Pacific Biologics CDMO market is anticipated to surge from $3.1 billion in 2023 to $5.9 billion by 2028, displaying an impressive CAGR of 13.7% during the same forecast period.
  • The report further categorizes the global market for Biologics CDMO by cell line type, including mammalian, microbial, and other modalities.
  • The mammalian segment is projected to grow from $8.7 billion in 2022 to $18.2 billion by 2028, boasting a CAGR of 12.9% over this period.

FUJIFILM Diosynth Biotechnologies Celebrates Site Unveiling for North Carolina Large-Scale Cell Culture Manufacturing Facility

Retrieved on: 
Tuesday, November 7, 2023
Fujifilm Diosynth Biotechnologies, Gold, Biodiversity, Wetland, Water, ESG, LEED, Vaccine, Therapy, Local government, Certification, CDMO, Biophysical environment, Sustainable Value, Engineering, Jacobs, Growth, Medicine, Risk, Potyvirus, CO2, Patient, Commerce, Fine chemical, Management, Social

HOLLY SPRINGS, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, and oncolytic viruses, today hosted a site unveiling celebration for its $2 billion large-scale cell culture manufacturing facility in Holly Springs.

Key Points: 
  • HOLLY SPRINGS, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, and oncolytic viruses, today hosted a site unveiling celebration for its $2 billion large-scale cell culture manufacturing facility in Holly Springs.
  • This site will also create 725 manufacturing jobs in North Carolina by the end of 2028.
  • Today’s Site Unveiling Celebration included remarks from FUJIFILM Diosynth Biotechnologies President and CEO, Lars Petersen, FUJIFILM Diosynth Biotechnologies Executive Vice President and Chief Operating Officer, Large-Scale Business Unit, Kenneth Bilenberg, and Jacobs President and CEO, Bob Pragada.
  • Jacobs is serving as engineering, procurement, and construction management partner for the FUJIFILM Diosynth Biotechnologies Holly Springs site.